Literature DB >> 27725869

MiR-300 suppresses laryngeal squamous cell carcinoma proliferation and metastasis by targeting ROS1.

Wensheng Ge1, Chaodong Han1, Jing Wang1, Yunping Zhang2.   

Abstract

Laryngeal squamous cell carcinoma (LSCC) is a common aggressive head and neck cancer with high mortality and incidence. MicroRNAs (miRNAs) are short, non-coding and endogenous RNAs that posttranscriptionally inhibit gene expression. In this study, we showed that miR-300 expression was downregulated in LSCC tissues compared with adjacent no-tumor tissues. MiR-300 overexpression inhibited Hep-2 cell proliferation, as well as the expression of ki-67 and PCNA. Moreover, overexpression of miR-300 repressed the cell invasion in Hep-2 cells. We identified c-ros oncogene 1 receptor tyrosine kinase (ROS1) as a direct target gene of miR-300 in Hep-2 cell. Furthermore, ROS1 expression was upregulated in LSCC tissues compared with adjacent no-tumor tissues. Interesting, there were an inverse correlation between ROS1 and miR-300 expression in the LSCC tissues. Overexpression of ROS1 increased the Hep-2 cells proliferation and invasion. Overexpression of ROS1 abrogated miR-300 induced cell growth and invasion inhibition. Therefore, our data suggested that miR-300 acted as a tumor suppressive gene in LSCC.

Entities:  

Keywords:  Laryngeal squamous cell carcinoma; ROS1; miR-300; miRNAs; microRNAs

Year:  2016        PMID: 27725869      PMCID: PMC5040687     

Source DB:  PubMed          Journal:  Am J Transl Res            Impact factor:   4.060


  48 in total

Review 1.  ROS1 Kinase Inhibitors for Molecular-Targeted Therapies.

Authors:  M M Al-Sanea; A Z Abdelazem; B S Park; K H Yoo; T Sim; Y J Kwon; S H Lee
Journal:  Curr Med Chem       Date:  2016       Impact factor: 4.530

2.  Methylation of microRNA-9 is a specific and sensitive biomarker for oral and oropharyngeal squamous cell carcinomas.

Authors:  Jacob Minor; Xiaotian Wang; Fang Zhang; John Song; Antonio Jimeno; Xiao-Jing Wang; Xian Lu; Neil Gross; Molly Kulesz-Martin; Daren Wang; Shi-Long Lu
Journal:  Oral Oncol       Date:  2011-11-30       Impact factor: 5.337

3.  MiR-300 regulate the malignancy of breast cancer by targeting p53.

Authors:  Xiao-Heng Xu; Da-Wei Li; Hui Feng; Hong-Mei Chen; Yan-Qiu Song
Journal:  Int J Clin Exp Med       Date:  2015-05-15

4.  miR-24 functions as a tumor suppressor in Hep2 laryngeal carcinoma cells partly through down-regulation of the S100A8 protein.

Authors:  Yan Guo; Weineng Fu; Hong Chen; Chao Shang; Ming Zhong
Journal:  Oncol Rep       Date:  2011-11-30       Impact factor: 3.906

Review 5.  MicroRNA dysregulation in uveal melanoma: a new player enters the game.

Authors:  Zheng Li; Xin Yu; Jianxiong Shen; Yang Jiang
Journal:  Oncotarget       Date:  2015-03-10

6.  The Frequency and Clinical Implication of ROS1 and RET Rearrangements in Resected Stage IIIA-N2 Non-Small Cell Lung Cancer Patients.

Authors:  Sha Fu; Ying Liang; Yong-Bin Lin; Fang Wang; Ma-Yan Huang; Zi-Chen Zhang; Jing Wang; Wen-Jian Cen; Jian-Yong Shao
Journal:  PLoS One       Date:  2015-04-23       Impact factor: 3.240

7.  MiR-33a suppresses breast cancer cell proliferation and metastasis by targeting ADAM9 and ROS1.

Authors:  Chuankai Zhang; Yunda Zhang; Weiji Ding; Yancheng Lin; Zhengjie Huang; Qi Luo
Journal:  Protein Cell       Date:  2015-10-27       Impact factor: 14.870

8.  MiR-27a regulates apoptosis in nucleus pulposus cells by targeting PI3K.

Authors:  Gang Liu; Peng Cao; Huajiang Chen; Wen Yuan; Jianxi Wang; Xianye Tang
Journal:  PLoS One       Date:  2013-09-25       Impact factor: 3.240

9.  The microRNA expression signature of bladder cancer by deep sequencing: the functional significance of the miR-195/497 cluster.

Authors:  Toshihiko Itesako; Naohiko Seki; Hirofumi Yoshino; Takeshi Chiyomaru; Takeshi Yamasaki; Hideo Hidaka; Tomokazu Yonezawa; Nijiro Nohata; Takashi Kinoshita; Masayuki Nakagawa; Hideki Enokida
Journal:  PLoS One       Date:  2014-02-10       Impact factor: 3.240

10.  Snail-regulated MiR-375 inhibits migration and invasion of gastric cancer cells by targeting JAK2.

Authors:  Yanjun Xu; Juan Jin; Yiman Liu; Zhenxia Huang; Yujie Deng; Tao You; Tianhua Zhou; Jianmin Si; Wei Zhuo
Journal:  PLoS One       Date:  2014-07-23       Impact factor: 3.240

View more
  7 in total

1.  MIR-300 in the imprinted DLK1-DIO3 domain suppresses the migration of bladder cancer by regulating the SP1/MMP9 pathway.

Authors:  Huaqing Yan; Jiangfeng Li; Yufan Ying; Haiyun Xie; Hong Chen; Xin Xu; Xiangyi Zheng
Journal:  Cell Cycle       Date:  2018-12-18       Impact factor: 4.534

2.  Retracted Article: Long noncoding RNA DLEU1 promotes cell proliferation and migration of Wilms tumor through the miR-300/HOXC8 axis.

Authors:  Wen'an Ge; Shengxing Wang
Journal:  RSC Adv       Date:  2019-12-04       Impact factor: 4.036

3.  miR‑300 regulates tumor proliferation and metastasis by targeting lymphoid enhancer‑binding factor 1 in hepatocellular carcinoma.

Authors:  Yufo Chen; Yuanyuan Guo; Yawei Li; Jingwen Yang; Jing Liu; Qiong Wu; Rui Wang
Journal:  Int J Oncol       Date:  2019-02-13       Impact factor: 5.650

4.  Circular RNA UBAP2 facilitates the cisplatin resistance of triple-negative breast cancer via microRNA-300/anti-silencing function 1B histone chaperone/PI3K/AKT/mTOR axis.

Authors:  Leiming Wang; Xi Yang; Fei Zhou; Xuesi Sun; Shulin Li
Journal:  Bioengineered       Date:  2022-03       Impact factor: 3.269

5.  [MiR-300 inhibits invasion and metastasis of osteosarcoma cell MG63 by negatively regulating PTTG1].

Authors:  D Liang; X Wu; J Bai; L Zhang; C Yin; W Zhong
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2021-02-25

6.  MicroRNA-300 suppresses metastasis of oral squamous cell carcinoma by inhibiting epithelial-to-mesenchymal transition.

Authors:  Yuanyuan Kang; Ying Zhang; Yan Sun; Yan Wen; Fuli Sun
Journal:  Onco Targets Ther       Date:  2018-09-10       Impact factor: 4.147

7.  MicroRNA-300 Inhibits the Proliferation and Metastasis of Cervical Cancer Cells via Posttranscriptional Suppression of G Protein-Coupled Receptor 34 (GPR34).

Authors:  Mei Wang; Ying Tian; Lin Miao; Wenxia Zhao
Journal:  J Oncol       Date:  2021-12-14       Impact factor: 4.375

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.